RealTime Laboratories has introduced a 31-marker urinary mycotoxin panel, adding 16 new fungal metabolites and using proprietary hydrolysis with LC-MS/MS to improve mold and toxin detection.
CMS has released preliminary 2027 CLFS rates, with data showing weighted median payment cuts for over 1,100 test codes; annual reductions are capped at 15% from 2027 to 2029 under current policy.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.
The Association for Diagnostics & Laboratory Medicine recommends that AI tools in clinical labs remain under existing CLIA oversight, citing the need for established validation and monitoring standards in response to a federal RFI.
The University of Reading has developed the TRIPLEcheck assay to personalize antiplatelet therapy by assessing platelet reactivity, with a 400-patient clinical trial underway.
